Dr. Seth Sherman performs cell-free knee cartilage repair implantation: 3 things to know about the FDA study

Written by Shayna Korol | February 05, 2019 | Print  |

Seth L. Sherman, MD, enrolled and operated on four patients in a study of CartiHeal's Agili-C knee cartilage repair implant.  

Three things to know:

1. Dr. Sherman is a board-certified orthopedic sports medicine surgeon at Columbia-based Missouri Orthopaedic Institute. He is one of 15 primary investigators in the U.S. conducting the FDA investigational device exemption study of the Agili-C implant.

2. The Agili-C implant is a cell-free implant made of inorganic sea coral exoskeleton. It is designed to be used for a variety of cartilage defects.

3. Patients are randomly assigned to either one of the traditional surgical options — microfracture or debridement — or to receive the new implant.

"Often in studies like this one, we can enroll only a very strict sub-set of young, active patients with a single, isolated cartilage defect," said Dr. Sherman. "In reality, that's not the typical patient we see every day. This implant is different because it's medically indicated for a wide range of situations including patients with multiple cartilage defects and even those with mild-moderate osteoarthritis."

More articles on biologics:
CollPlant names new board chairman: 4 insights
Ortho RTi releases results of 2 regenerative medicine studies
California neuroscience institute joins regenerative medicine clinical trial: 5 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months